Search
Research
Potential impact of a maternal vaccine for RSV: A mathematical modelling studyRespiratory syncytial virus is a major cause of respiratory morbidity and one of the main causes of hospitalisation in young children.
Research
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexityThere has been a coordinated effort from academic institutions and the PI to identify biomarkers that can predict immune checkpoint blockade response in cancer.
Research
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert NetworkThis report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season
Research
An observational study of febrile seizures: The importance of viral infection and immunizationDetermine the frequency of detection of specific viral pathogens in children with febrile seizures
Research
Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccinationEarly 7vPCV schedules have limited impact on pneumococcal vaccine type carriage in PNG
Research
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 yearsIn women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18
Research
Australia-wide point prevalence survey of antimicrobial prescribing in neonatal units: How much and how good?This is the first Australia-wide point prevalence survey of neonatal antimicrobial prescribing in tertiary children's hospitals.
Research
Group a streptococcal carriage and seroepidemiology in children up to 10 years of age in Australia.This study aimed to acquire nationally representative epidemiological data on GAS in Australia to scope the appropriate age for vaccination with a potential...
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean childrenInvasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.